

Anti-CD20 Sample Collections
Date Current as of March 3, 2010

Study Time Point	Treatment						Placebo					
	BAA	HLA	EBV/CMVP CR	EBV/CMV Serology	HepA/ Tetanus	SRLG	BAA	HLA	EBV/CMV PCR	EBV/CMV Serology	HepA/ Tetanus	SRLG
Screening	65	63	0	0	0	66	43	34	0	0	0	35
Baseline	0	0	33	21	0	44	0	0	22	10	0	34
2 weeks	0	0	32	14	0	12	0	0	19	7	0	14
5 weeks	60	0	29	15	0	15	37	0	18	6	0	10
12 weeks	62	0	28	17	1	13	36	0	20	3	0	12
19 weeks	0	0	22	13	0	13	0	0	18	6	0	12
26 weeks	60	1	27	16	0	41	33	0	17	2	0	27
39 weeks	53	0	26	16	0	10	34	0	12	2	0	12
52 weeks	57	0	0	0	22	2	32	0	0	0	19	0
56 weeks	0	0	21	12	23	30	0	0	14	2	14	26
78 weeks	68	0	55	46	1	72	39	0	36	27	0	51
104 weeks	54	0	53	50	39	58	32	0	29	25	16	33
30 months	40	0	0	0	0	41	22	0	0	0	0	23
36 months	8	0	0	0	0	9	3	0	0	0	0	3
PRN	1	0	2	2	12	0	3	0	0	0	8	4

Study Time Point	Responder						Non-Responder					
	BAA	HLA	EBV/CMVP CR	EBV/CMV Serology	HepA/Tetanus	SRLG	BAA	HLA	EBV/CMVP CR	EBV/CMV Serology	HepA/ Tetanus	SRLG
Screening	50	47	0	0	0	56	56	45	0	0	0	43
Baseline	0	0	34	21	0	46	0	0	21	10	0	32
2 weeks	0	0	31	16	0	15	0	0	20	5	0	11
5 weeks	49	0	31	15	0	17	46	0	16	6	0	8
12 weeks	52	0	32	14	1	15	44	0	16	6	0	10
19 weeks	0	0	28	13	0	15	0	0	12	6	0	10
26 weeks	47	0	26	12	0	40	46	1	18	6	0	28
39 weeks	46	0	20	10	0	12	40	0	18	8	0	10
52 weeks	47	0	0	0	26	0	41	0	0	0	15	2
56 weeks	0	0	21	10	23	32	0	0	14	4	14	24
78 weeks	57	0	50	37	0	73	48	0	39	34	1	48
104 weeks	44	0	42	35	26	53	41	0	39	39	28	37
30 months	33	0	0	0	0	34	29	0	0	0	0	30
36 months	6	0	0	0	0	7	5	0	0	0	0	5
PRN	1	0	2	2	12	2	3	0	0	0	8	2